Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase
Laurie D. Smith(Children's Mercy Hospital), Gregory M. Pastores(New York University), Suma P. Shankar(Emory University), Hak‐Myung Lee(Takeda (United States)), Ashish Bavdekar(King Edward Memorial Hospital Research Centre), Rebecca Mardach(Kaiser Permanente), Nicola Longo(Center for Human Genetics), Eric Crombez(University of California, Los Angeles), Thomas N. Hangartner(Wright State University), Paul Harmatz(Unknown), Joel Charrow(Northwestern University), William J. Rhead(Children's Hospital of Wisconsin)
Cited by 38
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
|Journal of Medical Genetics|2015|363
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302